The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funding for Shire’s Revestive as a treatment for short bowel syndrome (SBS). The National Institute ...

Shire plcSHPG announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion for the label expansion of Revestive ...

SBS is a rare and highly disabling condition that impacts patients' quality of life and can lead to serious life-threatening complications Teduglutide has received orphan drug designation for the ...

Takeda’s Revestive has become the first drug available in Europe for the treatment of short bowel syndrome, a condition caused by the surgical removal of a patient’s small intestine due to Crohn’s ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Shire plcSHPG announced that the European Commission has granted an extension of the market authorization for its gastrointestinal drug (GI) Revestive for use in the pediatric population. Revestive 5 ...

London, UK – Feb 10, 2020, Takeda is pleased to announce that the Scottish Medicines Consortium has accepted Revestive (teduglutide) for use in adult patients with short bowel syndrome (SBS), after ...

TORONTO, May 5, 2026 /CNW/ - Takeda Canada Inc. ("Takeda") announced that REVESTIVE ® (teduglutide for injection) will now be reimbursed by BC PharmaCare for eligible pediatric and adult patients with ...

- SBS is a rare and highly disabling condition that impacts patients' quality of life and can lead to serious life-threatening complications. - Teduglutide has received orphan drug designation for the ...